U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H35N3O2
Molecular Weight 421.575
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MAZAPERTINE

SMILES

CC(C)OC1=C(C=CC=C1)N2CCN(CC3=CC=CC(=C3)C(=O)N4CCCCC4)CC2

InChI

InChIKey=ZKZFPRUSWCYSGT-UHFFFAOYSA-N
InChI=1S/C26H35N3O2/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C26H35N3O2
Molecular Weight 421.575
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Mazapertine (RWJ-37796) is an arylpiperazine antipsychotic with high affinity to dopamine D2 and D3, serotonin 5-HT1A and alpha 1A-adrenergic receptors. It was being studied in the treatment of schizophrenia.

Originator

Johnson & Johnson
15

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
Adrenergic receptor alpha-1
169
Antagonist
2,778
 1.3 nM [Ki]
Serotonin 1a (5-HT1a) receptor
172
Antagonist
2,778
 1.7 nM [Ki]
Dopamine D2 receptor
297
Antagonist
2,778
 2.2 nM [Ki]

PubMed

Sample Use Guides

In Vivo Use Guide
healthy male subjects received incremental oral doses of mazapertine (from 5 to 50 mg over 7 days; n = 10) or placebo (n = 3) in part I and single doses in parts II (20 or 30 mg or placebo) and III (40 mg or placebo) in a double-blind fashion.
Route of Administration: Oral
Substance Class Chemical
Record UNII
N0X1XW704P
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966